Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 14/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402789 | 0.84 | LCK (0.52) | CA1CA2LCKPI4KB | |
| SCHEMBL1268366 | 0.83 | LCK (0.46) | CA1CA2LCKPI4KB | |
| SCHEMBL20421990 | 0.83 | CA1 (0.44) | CA1CA2LCKPI4KB | |
| SCHEMBL27459069 | 0.81 | CA1 (0.42) | CA1CA2LCKPI4KB | |
| SCHEMBL31214147 | 0.81 | CA1 (0.42) | CA1CA2LCKPI4KB | |
| SCHEMBL1563222 | 0.79 | LCK (0.48) | CA1CA2LCKPI4KB | |
| SCHEMBL15186149 | 0.78 | LCK (0.53) | CA1CA2LCKPI4KB | |
| SCHEMBL12056453 | 0.78 | LCK (0.53) | CA1CA2LCKPI4KB | |
| SCHEMBL31488298 | 0.77 | LCK (0.52) | CA1CA2LCKPI4KB | |
| SCHEMBL367076 | 0.77 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12275728-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3930849-B1 | THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240308995-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2024-09-19 | — | — | US | disclosed |
| CN-113166137-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranoside enzyme inhibitors | 比奥根MA公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. | 2013-09-26 | — | — | US | disclosed |
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| EP-2593277-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012006760-A1 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009000-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012008999-A2 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | GRM3, GRM6, GRM1 | CA1 1272/4885CA2 996/4885LCK 2208/4885 |
| US-12180205-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, MAN2A1, ENGASE | CA1 797/4885CA2 293/4885LCK 3944/4885 |
| US-20240308995-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MGAT3, MAN2A1, ENGASE | CA1 797/4885CA2 293/4885LCK 3944/4885 |
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | CA1 2768/4885CA2 1306/4885LCK 1700/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CA1 4519/4885CA2 4226/4885LCK 4407/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | CA1 3657/4885CA2 1110/4885LCK 313/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | CA1 3346/4885CA2 904/4885LCK 473/4885 |
| US-12275728-B2 | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | MGAT3, MAN2A1, ENGASE | CA1 797/4885CA2 293/4885LCK 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.